All Stories

  1. Polybodies for the treatment of respiratory syncytial virus infection
  2. Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions
  3. Challenges and advances in the development of antidotes against A-series nerve agents
  4. Efficacy and safety of transcutaneous electrical nerve stimulation versus oxybutynin in the treatment of overactive bladder in children: a systematic review and meta-analysis
  5. Amino acid deprivation vs. mainstream cancer therapeutics: exploring the potential and limitations
  6. Human Paraoxonase 1: From Bloodstream Enzyme to Disease Fighter & Therapeutic Intervention
  7. Neuroprotective potential of ApoE-mimetic peptide (ApoEFrag) in stroke models: Neurobehavioural and mechanistic study
  8. Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α
  9. Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy
  10. What are biopharmaceuticals?
  11. ApoE potential in CNS drugs targeting and as CNS therapeutic
  12. Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
  13. Endostatin in disease modulation: From cancer to beyond
  14. Role of paraoxonase 1 in organophosphate G-series nerve agent poisoning and future therapeutic strategies
  15. Polybodies: Next-generation clinical antibodies
  16. Broad-spectrum anti-cancer activity of fused human arginase variants
  17. Warfare Nerve Agents and Paraoxonase-1 as a Potential Prophylactic Therapy against Intoxication
  18. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies
  19. Treating liver cancer through arginine depletion
  20. Polyvalency: an emerging trend in the development of clinical antibodies
  21. Towards development of biobetter: L-asparaginase a case study
  22. Catalysing and Accelerating a New Phase in Indian Biopharma
  23. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
  24. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
  25. Development and characterization of fused human arginase I for cancer therapy
  26. Human arginase I: a potential broad-spectrum anti-cancer agent
  27. Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning
  28. Polyspecificity - An emerging trend in the development of clinical antibodies
  29. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning
  30. Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review
  31. Apolipoprotein-mimetic Peptides: Current and Future Prospectives
  32. Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective
  33. Human arginase 1, a Jack of all trades?
  34. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective
  35. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  36. Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett–Burman and central composite design in E. coli SE1
  37. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead
  38. APOE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation
  39. Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?
  40. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
  41. Antibiotic-free expression system for the production of human interferon-beta protein
  42. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies
  43. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead
  44. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning
  45. Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
  46. Abstract 12419: Preclinical Safety and Efficacy of a Novel Thrombolytic Agent Administered by Rapid Bolus Injection: Clot Specific Streptokinase (CSSK/SMRX-11)
  47. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation
  48. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
  49. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles
  50. Improving storage stability of recombinant organophosphorus hydrolase
  51. Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
  52. Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function
  53. Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life
  54. Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives
  55. Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
  56. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1
  57. Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
  58. Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs
  59. The Chemical Nature of the Polar Functional Group of Oxidized Acyl Chain Uniquely Modifies the Physicochemical Properties of Oxidized Phospholipid-Containing Lipid Particles
  60. Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides
  61. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function
  62. Characterization of Oxidized Phospholipid containing Reconstituted High Density Lipoprotein Particle
  63. A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit
  64. Closely related oxidized phospholipids differentially modulate the physicochemical properties of lipid particles
  65. Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase
  66. Contribution of Subdomain Structure to the Thermal Stability of the Cholera Toxin A1 Subunit
  67. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids
  68. Stabilization of the Tertiary Structure of the Cholera Toxin A1 Subunit Inhibits Toxin Dislocation and Cellular Intoxication
  69. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A2 possesses antibacterial activity
  70. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E
  71. Preferential binding of apolipoprotein E derived peptides with oxidized phospholipid
  72. Bax C-Terminal Peptide - Insights Into Membrane Interactions
  73. Conformational Instability of the Cholera Toxin A1 Polypeptide
  74. The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome
  75. Isoform-Specific Membrane Insertion of Secretory Phospholipase A2 and Functional Implications
  76. Structural and Functional Effects of Tryptophans Inserted into the Membrane-binding and Substrate-binding Sites of Human Group IIA Phospholipase A2
  77. Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
  78. Evidence for the Regulatory Role of the N-terminal Helix of Secretory Phospholipase A2 from Studies on Native and Chimeric Proteins
  79. Positioning Membrane Proteins by Novel Protein Engineering and Biophysical Approaches
  80. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase
  81. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids, by
  82. The N-terminal α-Helix of Pancreatic Phospholipase A2 Determines Productive-mode Orientation of the Enzyme at the Membrane Surface
  83. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids
  84. Oxidation of Goat Hepatic Galectin-1 Induces Change in Secondary Structure
  85. Involvement of a Nine-residue Loop of Streptokinase in the Generation of Macromolecular Substrate Specificity by the Activator Complex through Interaction with Substrate Kringle Domains
  86. Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo
  87. Carbohydrate induced modulation of cell membrane VII. Binding of exogenous lectin increases osmofragility of erythrocytes
  88. Carbohydrate induced modulation of cell membrane. VI. Binding of exogenous lectin induces susceptibility of erythrocytes to free radical damage: a spin label study